CAR T-cell safety, Sjögren’s pipeline to headline ACR Convergence
ACR Convergence 2026 has come at a potentially pivotal time for multiple diseases and therapy types across autoimmune and rheumatic diseases, ranging from chimeric antigen receptor T-cell therapy to lupus and Sjögren’s disease.
Slated for Nov. 6 to Nov. 11 in Orlando, Fla., this year’s meeting promises no shortage of new data on these and other pressing topics in rheumatology, including AI, GLP-1 receptor agonists and the safety of cellular therapy, particularly following the recent deaths reported in the Novartis and Bristol Myers Squibb CAR-T autoimmune disease trials.
To help attendees of